Literature DB >> 10467378

Quantification of impairment in MS: discussion of the scales in use.

M P Amato1, G Ponziani.   

Abstract

Accurate, efficient measurement of disease status has become a key issue in MS clinical practice and research. Despite some perceived problems, the Expanded Disability Status Scale (EDSS) remains the most widely used comprehensive measure of impairment. There is also a place for more restricted scales of impairment which focus on some aspects of neurological function in more detail than the EDSS e.g. measures of ambulation, arm function and cognitive function. Improvements in scales of impairment in the future is likely to result from the use of more quantitative tests of selected components of the neurological examination.

Mesh:

Year:  1999        PMID: 10467378     DOI: 10.1177/135245859900500404

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  11 in total

Review 1.  Secondary Progressive Multiple Sclerosis: Definition and Measurement.

Authors:  Domenico Plantone; Floriana De Angelis; Anisha Doshi; Jeremy Chataway
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

2.  Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis.

Authors:  Sara Leddy; Shahrzad Hadavi; Andrew McCarren; Gavin Giovannoni; Ruth Dobson
Journal:  J Neurol       Date:  2013-06-27       Impact factor: 4.849

Review 3.  What We Learned from The History of Multiple Sclerosis Measurement: Expanded Disability Status Scale.

Authors:  Bilge Piri Çinar; Yüksel Güven Yorgun
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

Review 4.  Neurostatus and EDSS Calculation with Cases.

Authors:  Sedat Şen
Journal:  Noro Psikiyatr Ars       Date:  2018       Impact factor: 1.339

5.  Spinal cord quantitative MRI discriminates between disability levels in multiple sclerosis.

Authors:  Jiwon Oh; Shiv Saidha; Min Chen; Seth A Smith; Jerry Prince; Craig Jones; Marie Diener-West; Peter C M van Zijl; Daniel S Reich; Peter A Calabresi
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

Review 6.  Pharmacotherapy in Secondary Progressive Multiple Sclerosis: An Overview.

Authors:  Floriana De Angelis; Domenico Plantone; Jeremy Chataway
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

7.  Pain in patients with multiple sclerosis: a complex assessment including quantitative and qualitative measurements provides for a disease-related biopsychosocial pain model.

Authors:  Dominik Michalski; Stefanie Liebig; Eva Thomae; Andreas Hinz; Florian Then Bergh
Journal:  J Pain Res       Date:  2011-08-02       Impact factor: 3.133

8.  A predictive model for corticosteroid response in individual patients with MS relapses.

Authors:  Martin Rakusa; Stefan J Cano; Bernadette Porter; Afsane Riazi; Alan J Thompson; Jeremy Chataway; Todd A Hardy
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

9.  Linear Parameter Varying Identification of Dynamic Joint Stiffness during Time-Varying Voluntary Contractions.

Authors:  Mahsa A Golkar; Ehsan Sobhani Tehrani; Robert E Kearney
Journal:  Front Comput Neurosci       Date:  2017-05-19       Impact factor: 2.380

Review 10.  Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis.

Authors:  Sandra Meyer-Moock; You-Shan Feng; Mathias Maeurer; Franz-Werner Dippel; Thomas Kohlmann
Journal:  BMC Neurol       Date:  2014-03-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.